AST SpaceMobile
ASTS
$40.90
-0.56%
AST SpaceMobile is a pre-revenue-stage satellite communications company designing and manufacturing the BlueBird constellation of low Earth orbit satellites, which are intended to deliver cellular broadband directly to standard, unmodified smartphones — a space-based network designed to eliminate terrestrial coverage gaps. The company occupies a distinctive position as a first-mover attempting to build a direct-to-device (D2D) satellite-to-phone platform, backed by an extensive IP and patent portfolio and partnerships with major mobile network operators, though it remains a capital-intensive, pre-commercial enterprise with only nascent service revenue. The investor narrative has shifted decisively negative: management pushed the commercial launch target to 2027, a $1 billion convertible note offering in July 2026 reignited dilution fears, and intensifying competition from SpaceX's Starlink direct-to-cell efforts has pressured sentiment. These developments, combined with a stock that has lost more than half its value over the past year, have turned the debate toward cash runway, execution credibility, and whether the company's $3.7 billion liquidity position is sufficient to bridge the gap to commercialization.…
ASTS
AST SpaceMobile
$40.90
Related headlines
ASTS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AST SpaceMobile's 12-month outlook, with a consensus price target around $74.28 and implied upside of +81.6% versus the current price.
Average Target
$74.28
0 analysts
Implied Upside
+81.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$43 - $108
Analyst target range
Twelve analysts cover ASTS with a consensus recommendation of "hold" (mean rating 2.62 on a scale where lower is more bullish), and an average target price of $74.28 — implying roughly +82.7% upside from the current $40.66, a gap that reflects how far the stock has fallen below even cautious Street estimates rather than overwhelming bullishness. The distribution skews neutral-to-cautious: recent actions include Cantor Fitzgerald and Piper Sandler maintaining Overweight, UBS reiterating Neutral, Scotiabank upgrading to Sector Perform from Sector Underperform, B. Riley upgrading to Buy from Neutral, but Deutsche Bank downgrading to Hold from Buy and Barclays maintaining Underweight — a mixed tape that suggests analysts see value at these levels but lack conviction on near-term catalysts. The consensus is best characterized as cautiously constructive on a 12-24 month view while acknowledging the launch delay and dilution overhang. The target range is extremely wide — from a low of $42.50 (just 4.5% above the current price, essentially pricing in continued execution delays and margin compression) to a high of $108.00 (a +165.6% upside that assumes successful 2027 commercialization, multiple expansion, and a credible path to the $3.87 billion average revenue estimate). This ~2.5x spread between low and high signals very high uncertainty and low conviction — the Street is effectively guessing at a binary outcome. The estimated EPS average of $3.38 (range $2.41 to $4.42) is notable because it implies analysts expect a dramatic swing to profitability, which stands in stark contrast to the current -$0.77 quarterly EPS; investors should treat these forward estimates as highly speculative given the pre-commercial stage. With the stock trading below the average target but near the low end of the range, the setup favors patient, risk-tolerant investors with a long time horizon, while the high short ratio of 6.39 and beta of 2.71 warn that near-term volatility and further downside remain very real possibilities.
Drowning in data?
Find the real signal!
Bulls vs Bears: ASTS Investment Factors
The bear case currently carries stronger evidence: a 262x PS multiple, -$1.64 billion TTM free cash flow, a launch pushed to 2027, and a stock making new 52-week lows on heavy volume all point to unresolved execution and financing risk. The bull case rests almost entirely on the future — an $74.28 average target, $3.7 billion of liquidity to reach 2027, and a first-mover D2D platform — none of which is yet validated by recurring revenue. The single most important tension is whether the $3.7 billion liquidity bridge is genuinely sufficient to fund the constellation through 2027 without further equity issuance; if management demonstrates on-schedule satellite deployment and a funded path, the de-rated multiple could re-expand sharply, but another delay or capital raise would likely break the $39.87 support and force another leg lower.
Bullish
- Street target implies 83% upside: The 12-analyst consensus average target is $74.28 versus the $40.66 price, an +82.7% implied return, and even the lowest target of $42.50 sits 4.5% above the current quote. Recent actions skew constructive at these levels, with Cantor Fitzgerald and Piper Sandler maintaining Overweight and B. Riley upgrading to Buy from Neutral.
- Revenue inflecting off a tiny base: Q2 2026 revenue of $31.52 million grew 26.27% year-over-year from $1.156 million, with the Product segment contributing $24.43 million and Service $7.09 million. Gross margin also improved sequentially to 25.23% from 24.92% in Q1 2026, a modest but positive sign on unit economics.
- Liquidity funds the 2027 milestone: Cash of $2.72 billion at the end of Q2 2026 plus the $1 billion convertible note gives roughly $3.7 billion of liquidity, and a current ratio of 16.35 confirms no near-term solvency pressure. Against Q2 free cash flow burn of -$694.77 million, that buffer covers the build-out to the delayed 2027 commercial launch.
- De-rating has already been severe: The PS multiple compressed from 1,635x at Q1 2026 to 843x at Q2 2026 and 262x currently, while PB fell to 10.10x from a peak near 14.03x. The stock is 0.9% above its 52-week low of $39.87 and 69.45% below its peak, meaning much of the launch-delay and dilution news is now reflected in price.
Bearish
- Valuation still priced for perfection: At $40.66 the stock trades at 262x trailing sales and 126x EV/sales, versus 1-3x sales for telecom operators — a premium of roughly 100x. The forward revenue estimate of $3.87 billion implies the market is capitalizing a business that does not yet exist at scale, leaving no room for further slippage.
- Cash burn is enormous and accelerating: TTM free cash flow is -$1.64 billion and Q2 2026 alone burned -$694.77 million, driven by $597.62 million of capex. Cash fell from $3.46 billion in Q1 to $2.72 billion in Q2, and the company is funding itself through external financing rather than operations, making it hostage to open capital markets.
- Launch slipped to 2027, revenue lumpy: Management pushed the commercial launch target to 2027, and quarterly revenue is milestone-driven rather than recurring: $54.31 million in Q4 2025, $14.74 million in Q1 2026, $31.52 million in Q2 2026. Q2 net loss widened sequentially to -$230.91 million from -$191.01 million, with operating loss of -$297.58 million.
- Dilution and Starlink competition: The July 2026 $1 billion convertible note reignited dilution fears, and shares outstanding rose from 255.98 million at Q4 2025 to 299.06 million at Q2 2026. SpaceX's Starlink direct-to-cell push is intensifying competitive pressure on the same orbital and spectrum opportunity, pressuring both sentiment and pricing power.
ASTS Technical Analysis
ASTS is in a severe, sustained downtrend, with the 1-year price change at -54.57% and the current price of $40.66 sitting at just 0.9% above its 52-week low of $39.87 — effectively at the bottom of its 52-week range (high of $133.86). This positioning signals a falling-knife dynamic rather than a value opportunity: the stock has surrendered roughly 70% from its peak and is testing the floor of its annual trading band, a pattern consistent with capitulation and loss of institutional conviction. The relative strength versus the S&P 500 is stark, at -70.10% over one year, underscoring that this is idiosyncratic deterioration, not broad market weakness. Recent momentum confirms and accelerates the downtrend: the 1-month change of -31.40% and 3-month change of -29.65% show the decline is steepening rather than stabilizing, with the 6-month change of -52.46% indicating persistent selling pressure across every horizon. The 1-month relative strength of -32.62% versus SPY's +1.22% highlights a violent divergence from a rising market, and the most recent session alone saw an -8.55% drop on 17.1 million shares — elevated volume on down days typically signals distribution. With no RSI provided, the magnitude and velocity of the decline (a -69.45% max drawdown) suggest deeply oversold conditions that could produce technical bounces, but oversold readings in a structural downtrend are unreliable timing signals. Key levels are clear: support rests at the 52-week low of $39.87, and a decisive breakdown below that level would open the door to new lows and likely trigger further momentum-driven selling; resistance sits at the 52-week high of $133.86, a level so distant it is functionally irrelevant near-term, with intermediate resistance likely forming around the $50-58 zone where the stock consolidated in September. The beta of 2.706 is critical context — the stock is roughly 2.7x as volatile as the market, meaning position sizing must be dramatically reduced relative to a market-beta holding, and a 1% market move can translate to a ~2.7% move here, amplifying both drawdown risk and the potential for violent counter-trend rallies.
Beta
2.71
2.71x market volatility
Max Drawdown
-69.5%
Largest decline past year
52-Week Range
$39-$134
Price range past year
Annual Return
-48.0%
Cumulative gain past year
| Period | ASTS Return | S&P 500 |
|---|---|---|
| 1m | -33.9% | -0.1% |
| 3m | -30.9% | +4.7% |
| 6m | -46.5% | +8.3% |
| 1y | -48.0% | +15.2% |
| ytd | -51.0% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ASTS Fundamental Analysis
Revenue is inflecting but from a tiny base: Q2 2026 revenue of $31.52 million grew 26.27% year-over-year versus $1.156 million in Q2 2025, a dramatic step-up driven by the Product segment ($24.43 million) with Service contributing $7.09 million. However, the multi-quarter trend is volatile rather than smoothly accelerating — Q4 2025 posted $54.31 million before Q1 2026 fell to $14.74 million and Q2 rebounded to $31.52 million — reflecting lumpy, milestone-driven revenue recognition rather than a recurring commercial ramp. The critical caveat is that this revenue remains a rounding error against a $25.3 billion market cap, and the commercial launch delay to 2027 means the true service-revenue inflection is still ahead; the investment case rests entirely on future constellation deployment, not current top-line performance. Profitability remains deeply negative: Q2 2026 net income was -$230.91 million (a -7.33% net margin) with an operating loss of -$297.58 million and EBITDA of -$252.07 million, and the loss widened sequentially from Q1's -$191.01 million. Gross margin of 25.23% in Q2 improved from Q1's 24.92% but collapsed from Q4 2025's -68.11% (which reflected cost-of-revenue charges exceeding revenue), and the reported gross margin of 53.42% in the key metrics likely reflects a different period basis — either way, margins are far below what a scaled telecom operator would earn and are distorted by early-stage manufacturing costs. The trajectory is not toward near-term profitability: R&D of $7.77 million and G&A of $63.90 million in Q2, plus $26.08 million of interest expense, mean losses will persist until the constellation generates meaningful service revenue. Balance sheet liquidity is the company's strongest asset but is being consumed rapidly: cash at end of Q2 2026 stood at $2.72 billion (down from $3.46 billion in Q1), the current ratio is a robust 16.35, and debt-to-equity is 1.22 — but free cash flow TTM is -$1.64 billion and Q2 FCF alone was -$694.77 million, driven by $597.62 million of capex. ROE of -18.57% and ROA of -7.64% confirm capital destruction during the build-out phase, and the company is funding itself through external financing (the $1 billion convertible note, plus $2.34 billion of net financing inflows in Q4 2025) rather than internal cash generation — a structure that leaves it highly dependent on capital markets remaining open and on executing the satellite build on schedule.
Quarterly Revenue
$31520000.0B
2026-06
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
25.2%
Latest Quarter
Free Cash Flow
$-1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ASTS Overvalued?
Because ASTS has negative net income (-$230.91 million in Q2 2026) and negative EBITDA (-$252.07 million), the PE ratio is not meaningful — the trailing PE of -54.20 and forward PE of -31.60 are artifacts of losses, and EV/EBITDA of -68.19 is similarly unusable. The appropriate primary metric is therefore the price-to-sales ratio: at 262.16x trailing sales (and EV/Sales of 126.09x), the stock is priced at an extraordinary multiple that can only be rationalized by the market discounting a future, fully deployed constellation with billions in service revenue — the forward-looking analyst revenue estimate of $3.87 billion average (range $3.02 billion to $4.79 billion) implies the market is capitalizing a business that does not yet exist at scale. The gap between the trailing PS of 262x and the forward revenue estimates implies the market expects revenue to grow by orders of magnitude, embedding enormous execution risk into the current price. Peer comparison is difficult because ASTS has no direct public comp at scale, but against the Communication Services sector and telecom operators (which typically trade at 1-3x sales), the 262x PS represents a premium of roughly 100x or more — a spread that can only be justified by a winner-take-most D2D platform outcome, not by current fundamentals. The PB ratio of 10.10x versus a sector norm of 2-3x reinforces that investors are paying for intangible future optionality (spectrum, patents, orbital slots) rather than book assets. Historical context shows the multiple has compressed violently: the PS ratio was 843x at Q2 2026 reporting and 1,635x at Q1 2026, versus 342x at Q4 2025 — meaning the stock has de-rated sharply even as the denominator (revenue) has grown, a classic sign of multiple compression overwhelming fundamental improvement. The PB ratio of 10.10x is near the low end of its own recent range (which peaked around 14.03x in Q2 2026 and 13.04x in Q2 2025), suggesting the market has already repriced much of the optimism out — but with the stock at $40.66 and the PS still at 262x, "cheap" is a relative term; the valuation remains priced for perfection on a timeline that has now slipped to 2027.
PE
-54.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-68.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are acute. TTM free cash flow is -$1.64 billion with Q2 2026 alone at -$694.77 million against $597.62 million of capex, and cash fell from $3.46 billion in Q1 to $2.72 billion in Q2 — roughly four quarters of runway at the current burn before the $1 billion convertible note is layered in. Losses are widening, not narrowing: Q2 net income of -$230.91 million versus Q1's -$191.01 million, operating loss of -$297.58 million, EBITDA of -$252.07 million, and $26.08 million of quarterly interest expense. Revenue is lumpy and concentrated, swinging from $54.31 million in Q4 2025 to $14.74 million in Q1 2026, with the Product segment at $24.43 million of Q2's $31.52 million — a milestone-driven base that is a rounding error against a $25.3 billion market cap.
Market and competitive risks compound the financial ones. At 262x trailing sales and 126x EV/sales versus 1-3x for telecom operators, any multiple compression overwhelms fundamental improvement — PS already fell from 1,635x to 262x while revenue grew. Beta of 2.706 means a 1% market move translates to roughly 2.7% here, and the 1-month relative strength of -32.62% versus SPY's +1.22% shows violent idiosyncratic divergence. Recent news highlights the threats directly: the July 2026 $1 billion convertible note reignited dilution fears, SpaceX's Starlink direct-to-cell efforts are intensifying, and the commercial launch slipped to 2027 — each a discrete negative catalyst that has already driven a 33% July decline.
The worst-case scenario is a further launch slip or a dilutive equity raise before the 2027 milestone, which would break the $39.87 52-week low and trigger momentum-driven selling in a stock with a 69.45% max drawdown. From $40.66, a move to the 52-week low is only -1.9%, but a break below opens new lows, and the analyst low target of $42.50 offers essentially no downside cushion. A realistic adverse case of -35% to -50% (roughly $20-$26) is consistent with the stock's history of 69% peak-to-trough declines and would represent a further $7-10 billion of market cap erosion if the financing window tightens.
